|
|
 |
|
|
|
|
| |
|
|
| |
Mifepristone was discovered by researchers at Roussel Uclaf in France in the 1980s. They were studying antogonists to progesterone and glucocorticoid receptors. Clinical tests were initiated in 1982. Mifepristone was licensed in France in 1988. It was used in combination with a synthetic prostaglandin. Later that year, Roussel Uclaf said it would halt distribution of Mifepristone.
Two days later they resumed distribution. Mifepristone was approved in a other European nations, first in the United Kingdom and Scandanavia in 1992 and then followed by Germany in 1993. Many other European nations allowed use by 1999.
Roussel Uclaf did not seek U.S. FDA approval. Research was disrupted further when the first Bush administration banned importation in 1989. The ban on Mifepristone was not reversed until 1993. In 1994, Roussel Uclaf gave the U.S. rights to the Population Council and Mifepristone went on approvable status in 1996. Mifepristone production was intended to begin through the Danco Group in 1996 but they withdrew briefly in 1997. It was approved by the U.S. Food and Drug Administration in September, 2000. |
|
| |
| |
|
|
|
|
|
|